Ayala Pharmaceuticalsの将来のP / E

Ayala Pharmaceuticalsの将来のP / Eは何ですか。

Ayala Pharmaceuticals Inc.の将来のP / Eは-0.14です。

将来のP / Eの定義は何ですか。



未来比率P / E (株価収益率)は、企業の株価と今後12ヶ月間の1株当たり利益見込額との比率です。

The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.

NASDAQのセクタHealth Careにおける将来のP / Eの企業と比べるAyala Pharmaceuticals

Ayala Pharmaceuticalsは何をしますか。

advaxis (nasdaq: adxs) is a late -stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer. the advaxis technology, using bioengineered live attenuated bacteria, listeria monocytogenes (lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.

Ayala Pharmaceuticalsと類似の将来のp / e